On June 24, 2026 Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, reported that four oral and poster presentations highlighting data from its RAS(ON) pipeline will be featured at the 2026 European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Gastrointestinal Cancers Congress, taking place July 1–4, 2026 in Munich, Germany.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The program will include two oral presentations from Phase 1/2 trials evaluating zoldonrasib, an oral RAS(ON) G12D-selective covalent inhibitor, in combination regimens for patients with metastatic RAS G12D pancreatic ductal adenocarcinoma (PDAC). These presentations will report results from zoldonrasib plus chemotherapy in the first line setting, and zoldonrasib plus daraxonrasib, the company’s oral RAS(ON) multi-selective inhibitor, in patients who had received one or more prior lines of therapy.

Additional presentations will include two Phase 3 trials-in-progress posters for RASolute 303, evaluating daraxonrasib as a monotherapy or in combination with gemcitabine and nab-paclitaxel versus standard of care gemcitabine and nab-paclitaxel as a first line treatment for patients with metastatic PDAC, and RASolute 304, evaluating adjuvant daraxonrasib in patients with PDAC who have undergone resection and completed perioperative chemotherapy.

Details of Revolution Medicines’ presentations are listed below.

Revolution Medicines Oral Presentations:

Title: Safety and Efficacy of Zoldonrasib (RMC-9805) Plus Chemotherapy in Patients (pts) with 1L RAS G12D Metastatic Pancreatic Adenocarcinoma (mPDAC)
Abstract: #340O
Presenter: Brian Wolpin, M.D., Dana-Farber Cancer Institute
Session: Proffered Paper Session
Date/Time: July 2; 2:40 p.m. – 2:50 p.m. CEST

Title: Safety and Efficacy of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) in Patients with 2L+ KRAS G12D Metastatic Pancreatic Adenocarcinoma (mPDAC)
Abstract: #341O
Presenter: Nilofer Azad, M.D., Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Session: Proffered Paper Session
Date/Time: July 2; 2:50 p.m. – 3:00 p.m. CEST

Revolution Medicines Posters:

Title: RASolute 303: A Phase 3 Global, Multicenter, Open-Label, Randomized 3-Arm Study of Daraxonrasib Monotherapy or Daraxonrasib Plus Gemcitabine and Nab-paclitaxel Versus Gemcitabine and Nab-paclitaxel as a First Line Treatment for Patients With Metastatic Pancreatic Adenocarcinoma
Abstract: #471TiP
Presenter: Thomas Seufferlein, M.D., Ph.D., University Hospital Ulm
Session: Upper Digestive – Biliary, ampullary and pancreatic cancer
Date/Time: July 3; 3:30 p.m. – 4:30 p.m. CEST

Title: RASolute 304 – A Phase 3 Multicenter, Open-label, Randomized Study of Adjuvant Daraxonrasib Versus Observation Following Completion of Neoadjuvant and/or Adjuvant Chemotherapy in Patients With Resected Pancreatic Adenocarcinoma (PDAC)
Abstract: #472TiP
Presenter: Michel Ducreux, M.D., Ph.D., Institut Gustave Roussy
Session: Upper Digestive – Biliary, ampullary and pancreatic cancer
Date/Time: July 3; 3:30 p.m. – 4:30 p.m. CEST

(Press release, Revolution Medicines, JUN 24, 2026, View Source [SID1234668944])